The short answer
Aloe gel has not been shown to cause added hypoglycemia with insulin glargine. A small study with oral diabetes drugs cannot establish this combination’s safety or risk.
What this answer covers
Oral Aloe vera gel versus laxative latex, whole leaf and topical products. Glargine U100/U300 product differences retained.
- Supplement or preparation
- Aloe vera
- Medication ingredient
- insulin glargine
The human trial used other medicines
A small trial added aloe gel to glyburide and metformin, improving glucose measures and reporting no adverse effects in its abstract. It did not test insulin glargine.
A glucose improvement is not a risk rate
Lower average glucose does not itself demonstrate clinical hypoglycemia. The trial cannot quantify harm from the exact glargine combination, and a small study reporting no adverse effects does not prove safety.
Distinguish aloe preparations
Oral gel differs from latex and whole-leaf products; topical gel is a different route. Findings for a specified gel cannot be applied to every aloe supplement.
Follow the glargine product plan
Discuss the exact product and amount with the diabetes team and follow your glucose-monitoring and low-glucose treatment plan. Do not adjust insulin yourself. Lantus and Toujeo have different concentrations and switching instructions. Keep the prescribed product and schedule; do not switch doses on your own.
Evidence and practical considerations
Side effects & toxicity
Indirect oral-drug aloe-gel trial does not establish clinical hypoglycemia with exact glargine.
- Exact scope
- Oral Aloe vera gel versus laxative latex, whole leaf and topical products. Glargine U100/U300 product differences retained. with insulin glargine RxCUI274783 IN; single-insulin subcutaneous product, concentration and schedule specific.
- Medication form and route
- subcutaneous insulin glargine; oral supplement
What remains uncertain
- No exact event rate or arbitrary insulin change.
Factors that may matter: Product; Dose; Meals; Other diabetes treatment; Kidney and liver function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed LANTUS U-100
Hypoglycemia can be severe; meal, activity and glucose-active treatment changes can require increased monitoring and clinician review. No intravenous or pump use. Once daily at the same time each day. Product-specific switching instructions distinguish concentrations.
How this applies: Exact insulin glargine RxCUI274783 IN, single-insulin product scope. Combination products not assumed equivalent.
No exact supplement interaction rate. Long-acting insulin is not a rapid mealtime formulation; concentration and device matter.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed TOUJEO U-300
Hypoglycemia can be severe; meal, activity and glucose-active treatment changes can require increased monitoring and clinician review. No intravenous or pump use. Once daily at the same time each day. Product-specific switching instructions distinguish concentrations.
How this applies: Exact insulin glargine RxCUI274783 IN, single-insulin product scope. Combination products not assumed equivalent.
No exact supplement interaction rate. Long-acting insulin is not a rapid mealtime formulation; concentration and device matter.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Hyperlipidemic type2diabetes adults;30aloe and30placebo.
Aloe gel improved glucose measures with oral diabetes medicines; no adverse effects reported in the abstract.
How this applies: Indirect for exact insulin glargine; original study drug, preparation and endpoint retained.
Aloe gel with glyburide/metformin, not insulin glargine. Small trial and no reported adverse effects do not prove combination safety.
Source 4: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering different Aloe vera products.
Guidance distinguishes oral preparations and describes limited glucose-lowering research; latex can cause abdominal pain, cramps and diarrhea.
How this applies: Indirect for exact insulin glargine; original study drug, preparation and endpoint retained.
General botanical guidance does not establish exact insulin glargine interaction or equivalence of gel, latex and whole leaf.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact basal-insulin article with independently inspected product labels and original endpoint limits. | |
| Research summary published |
Article revision: a323f72dd6ba0176
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.